Ibrahim M L, Hassane H, Konate L, Adamou S, Ousmane I, Adehossi E, Jeanne I, Duchemin J B
Centre de recherche médicale et sanitaire (CERMES), BP 10887 Niamey, Niger.
Bull Soc Pathol Exot. 2008 Feb;101(1):47-9.
Plasmodium falciparum resistance to chloroquine first arose in Africa 25 years ago. Nowadays most of African malaria control programmes have switched their first-line treatment of uncomplicated malaria cases towards artemisinin derivatives combination. After WHO guidelines, a survey network for malaria treatment resistance has been set up in the Niger valley around Niamey since December 2004. The association of the Niger national malaria control programme with the CERMES research center allowed collecting of samples from both health centers and hospitals of this region. Blood finger-pricks on filter papers were tested for detection of plasmodial antigen in health center without biological diagnosis capacity. Specimens found positive either in hospital laboratory or by using antigen method were tested by PCR/RFLP to detect K76T mutations on the pfcrt gene and S108N mutation on the pfdhfr gene. This simple procedure allows the screening of a large number of specimens. Moreover, a spatial distribution of mutations and evidence of resistance clusters were searched integrating the data in a geographic information system. The 76T mutation of pfcrt and 108N of pfdhfr were respectively found in 50.8% and 57% of the specimens tested. No statistically significant difference was found according to the level of sanitary formations or the age of the patients. No resistance cluster was identified and the prevalence of mutation seems homogeneous in the zone. By completing the clinical efficacy studies we think that our simple method for collecting and testing blood samples associated with clinical efficacy studies may be useful for building a network of malaria drug resistance in Africa.
恶性疟原虫对氯喹的耐药性于25年前首次在非洲出现。如今,大多数非洲疟疾控制项目已将单纯性疟疾病例的一线治疗转向青蒿素衍生物联合用药。根据世界卫生组织的指导方针,自2004年12月起在尼亚美周围的尼日尔河谷建立了疟疾治疗耐药性调查网络。尼日尔国家疟疾控制项目与CERMES研究中心的合作使得能够从该地区的卫生中心和医院收集样本。在没有生物诊断能力的卫生中心,对滤纸上的血样进行疟原虫抗原检测。在医院实验室或采用抗原方法检测呈阳性的标本,通过聚合酶链反应/限制性片段长度多态性(PCR/RFLP)检测pfcrt基因上的K76T突变和pfdhfr基因上的S108N突变。这一简单程序能够筛查大量标本。此外,将数据整合到地理信息系统中,搜索突变的空间分布和耐药性聚集的证据。在检测的标本中,分别有50.8%和57%发现了pfcrt基因的76T突变和pfdhfr基因的108N突变。根据卫生机构级别或患者年龄,未发现统计学上的显著差异。未发现耐药性聚集现象,该区域的突变患病率似乎较为均匀。通过完成临床疗效研究,我们认为我们这种与临床疗效研究相关的简单血样采集和检测方法可能有助于在非洲建立疟疾耐药性监测网络。